Focus Partners Wealth
HRTX icon

Focus Partners Wealth’s Heron Therapeutics HRTX Stock Holding History

Focus Partners Wealth’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14K Sell
17,514
-130,956
-88% -$152K ﹤0.01% 2625
2025
Q4 		$3.57M Buy
148,470
+129,855
+698% +$160K ﹤0.01% 1084
2025
Q3 		$23.5K Buy
+18,615
New +$29.5K ﹤0.01% 2181
2025
Q1 		– Sell
-20,000
Closed -$30.6K – 1971
2024
Q4 		$30.6K Buy
+20,000
New +$32.4K ﹤0.01% 1837

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Focus Partners Wealth's HRTX Position: Q1 2026 in Review

Focus Partners Wealth reduced its Heron Therapeutics (HRTX) stake by 88% in Q1 2026, selling an estimated $152K and leaving 17,514 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #2625.

Focus Partners Wealth first reported a position in HRTX in Q4 2024 and has held it in 4 quarters since. The position peaked at $3.57M in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Focus Partners Wealth held 17,514 shares of Heron Therapeutics worth $14K as of Q1 2026.
  • Focus Partners Wealth sold 130,956 Heron Therapeutics shares in Q1 2026, an estimated $152K.
  • Heron Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2625 holding.
  • Focus Partners Wealth first reported a position in Heron Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Focus Partners Wealth's Heron Therapeutics position peaked at $3.57M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.